Physician profile
Jamie R Chu
NPI 1629496302
$1,010.94
in general payments reported to CMS, 2019-2025
15 companies · $288 in 2025
The $288 reported for 2025 was more than what 88% of Pediatric Emergency Medicine (Pediatrics) providers received nationally (typical 2025 total: $53.43).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $276 · 2024: $447 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $473.58 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $81.33 | 2023-2024 | Jornay Pm |
| Cranial Technologies, INC | $79.72 | 2023-2024 | Doc Band |
| Sanofi-Aventis U.S. LLC | $77.71 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $55.35 | 2023-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Ironwood Pharmaceuticals, INC | $37.27 | 2024 | |
| Aytu Biopharma, INC. | $30.31 | 2024-2025 | Karbinal |
| Ars Pharmaceuticals Operations, INC. | $28.76 | 2025 | Neffy |
| Pfizer INC. | $28.04 | 2024 | |
| Phadia US INC. | $24.55 | 2024 | Immunocap |
| Tris Pharma INC | $21.96 | 2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $21.36 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $18.94 | 2024 | Adzenys Xr-Odt |
| Verrica Pharmaceuticals INC. | $17.81 | 2025 | Ycanth |
| Supernus Pharmaceuticals, INC. | $14.25 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.